Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Droplet microfluidics for tumor drug-related studies and programmable artificial cells

Dimitriou, Pantelitsa, Li, Jin ORCID: https://orcid.org/0000-0002-4672-6806, Tornillo, Giusy, McCloy, Thomas and Barrow, David ORCID: https://orcid.org/0000-0003-2096-7262 2021. Droplet microfluidics for tumor drug-related studies and programmable artificial cells. Global Challenges 5 (7) , 2000123. 10.1002/gch2.202000123

[thumbnail of gch2.202000123.pdf] PDF - Published Version
Available under License Creative Commons Attribution.

Download (4MB)

Abstract

Anticancer drug development is a crucial step toward cancer treatment, that requires realistic predictions of malignant tissue development and sophisticated drug delivery. Tumors often acquire drug resistance and drug efficacy, hence cannot be accurately predicted in 2D tumor cell cultures. On the other hand, 3D cultures, including multicellular tumor spheroids (MCTSs), mimic the in vivo cellular arrangement and provide robust platforms for drug testing when grown in hydrogels with characteristics similar to the living body. Microparticles and liposomes are considered smart drug delivery vehicles, are able to target cancerous tissue, and can release entrapped drugs on demand. Microfluidics serve as a high-throughput tool for reproducible, flexible, and automated production of droplet-based microscale constructs, tailored to the desired final application. In this review, it is described how natural hydrogels in combination with droplet microfluidics can generate MCTSs, and the use of microfluidics to produce tumor targeting microparticles and liposomes. One of the highlights of the review documents the use of the bottom-up construction methodologies of synthetic biology for the formation of artificial cellular assemblies, which may additionally incorporate both target cancer cells and prospective drug candidates, as an integrated “droplet incubator” drug assay platform.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Biosciences
Engineering
European Cancer Stem Cell Research Institute (ECSCRI)
Publisher: Wiley
ISSN: 2056-6646
Funders: European Horizon 2020. Grant Number: 824060
Date of First Compliant Deposit: 11 May 2021
Date of Acceptance: 21 March 2021
Last Modified: 06 Jan 2024 03:31
URI: https://orca.cardiff.ac.uk/id/eprint/141156

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics